Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from MAPS Public Benefit Corporation

MDMA therapy for PTSD reaches FDA

MAPS Public Benefit Corporation submitted MDMA as a new drug application, making its approval more likely

Salon · Dec 14, 2023

15 Global Psychedelics Executives To Keep An Eye On In 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list of some of the top executives in the space to keep an eye on.

Benzinga · Oct 28, 2022

10 Psychedelics CEOs To Pay Attention To In 2022

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

Benzinga · Jun 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD

The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).

Benzinga · May 10, 2022

Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS

Numinus Wellness Inc. (OTCQX:NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by…

Benzinga · Mar 30, 2022

Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy

Michael Mullette, a former Moderna (NASDAQ:MNRA) vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient…

Benzinga · Mar 8, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Calgary

17 stories

Numinus Wellness Inc

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.